Published Guideline
READ GUIDELINE
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer" published in the Journal for ImmunoTherapy of Cancer (JITC) on July 15, 2021 and has since been updated.
Updated Content (last reviewed 3/15/24)
SITC continually evaluates the field for practice-changing data and new FDA approvals that may affect the guideline. The information on this page provides a detailed overview of updates to the guideline content. Updates to the guideline outlined below were made with the approval of SITC's Urothelial Cancer CPG Expert Panel. More information on SITC Guidelines can be found here.
v2.3 Update Summary
Based on the voluntary withdrawal by the manufacturer of the atezolizumab indication for the treatment of cisplatin- and platinum-ineligible patients with mUC, the Urothelial Cancer CPG has been updated in the Diagnostic tests and biomarkers for urothelial cancer immunotherapy, and Advanced/metastatic urothelial carcinoma sections as well as within the mUC treatment algorithm.
Based on the approval of nadofaragene firadenovec for the treatment of BCG-unresponsive NMIBC with CIS with or without papillary tumors, the Urothelial Cancer CPG has been updated in the Non-muscle invasive bladder cancer section including the NMIBC treatment algorithm.
Based on the approval of Enfortumab vedotin with pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy, the Urothelial Cancer CPG has been updated in the Advanced/metastatic urothelial carcinoma section and the mUC treatment algorithm.
v2.2 Update Summary
Based on the indication change for pembrolizumab for the treatment of patients with mUC, the Urothelial Cancer CPG has been updated in the following locations:
- Immunotherapies for First-line Treatment of mUC
- mUC Treatment Algorithm
v2.1 Update Summary
Based on the approval of nivolumab for the treatment of patients with urothelial cancer who are at high risk of recurrence after undergoing radical resection, the Urothelial Cancer CPG has been updated in the following locations:
- Phase III trials of adjuvant therapy for MIBC
- Immunotherapy with chemoradiation as bladder-sparing therapy
- mUC treatment algorithm
- Immunotherapies for first-line treatment of mUC
- Immunotherapies for R/R mUC